Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. (Q34002037)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. |
scientific article |
Statements
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer (English)
Johann Sebastian de Bono
Cora Sternberg
Joaquim Bellmunt
Jean Pierre Droz
Kurt Miller
Aude Flechon
Chris Parker
Gerhard Zugmaier
Veronica Hersberger-Gimenez
Louise Cockey